Sign In
Buy INMB
$2.09
+0.180 (+9.42%)
At Close: Aug 07, 2026
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
09:30am, Thursday, 24'th Oct 2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-sta
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
08:30am, Friday, 11'th Oct 2024
Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation an
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
05:04am, Monday, 30'th Sep 2024
INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with mCRPC released; Additional results from higher cohorts expected throughout
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
08:00am, Thursday, 26'th Sep 2024
BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK
BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional
INmune Bio Announces $13.0 Million Registered Direct Offering
08:30am, Friday, 13'th Sep 2024
Boca Raton, Florida, Sept. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company focused on developi
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
09:00am, Tuesday, 03'rd Sep 2024
Boca Raton, Florida, Sept. 03, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments t
INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript
11:50pm, Thursday, 01'st Aug 2024
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscien
INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update
04:05pm, Thursday, 01'st Aug 2024
Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation an
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: IN
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
08:00am, Thursday, 25'th Jul 2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
08:45am, Tuesday, 23'rd Jul 2024
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics
INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro
06:12am, Monday, 08'th Jul 2024
INmune Bio is developing immunotherapies for cancer and Alzheimer's, focusing on TNF and NK cell platforms. Their lead drug candidate, XPro, is in Phase 2 trials for early Alzheimer's disease and has
INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection
09:57am, Friday, 05'th Jul 2024
INmune Bio focuses on late-stage therapy for Alzheimer's disease and natural killer cell therapy. XPro is the main focus for Alzheimer's disease, showing promising results with ongoing phase 2 study.
INmune Bio Inc. to Join Russell 3000® Index
08:00am, Thursday, 30'th May 2024
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russel
